Diabetes Mellitus, Type 2NCT04950283
MR-based Characterization of Bone Marrow in Its Relevance to Skeletal Disease in Patients With Diabetes
An observational study of Diabetes Mellitus, Type 2 and Osteoporosis, run by University Hospital Tuebingen at 1 site in Germany.
Trial summary
For a long time, no direct connection was seen between the two common diseases diabetes mellitus and osteoporosis. However, as more and more younger people are affected by obesity, develop type 2 diabetes mellitus and suffer osteoporotic fractures, the question of a connection between these clinical pictures has now… Read more about this study
- Who is it for?
- Ages 25 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Diabetes Mellitus, Type 2, Osteoporosis, Insulin Resistance
- What is being tested?
- magnetic resonance examination, anthropometric and metabolic characterization
- Type of treatment
- Pill or oral medicine
- How many people
- 85 participants
- Where
- 1 siteGermany
- Study dates
- 7 Jul 2021to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: community sample
Who may be able to join
- Body mass index between 18,5 and 35 kg/m²
- Age between 25 and 75 years
- Ability to understand and follow study-related instructions
- Consent to information in case of unexpected detected pathological findings
Who cannot join
- contraindications for magnetic resonance imaging (metal in or on the body, e.g. pacemaker)
- pregnancy
- people with limited thermal sensors or increased sensitivity to heating
- Persons in whom circulatory disease cannot be excluded after questioning
- Individuals who report a hearing disorder or increased sensitivity to loud sounds
- Claustrophobia
Show all 13Show fewer
- subjects incapable of giving consent are excluded
- acute illness or infection within the last 4 weeks
- Conditions that, in the judgment of an investigator, jeopardize the success of the study or indicate that the subject is at risk of harm
- type 1 diabetes
- Patients with type 2 diabetes and pharmacologic therapy for diabetes outside of metformin and DPP-IV inhibitors
- HbA1c > 10,0 %
- duration of diabetes >= 2 years
Trial locations and contacts
1 site in 1 country.
About this study
Official title: MR-basierte Charakterisierung Des Knochenmarks in Seiner Bedeutung für Skeletterkrankungen Von Patienten Mit Diabetes
For a long time, no direct connection was seen between the two common diseases diabetes mellitus and osteoporosis. However, as more and more younger people are affected by obesity, develop type 2 diabetes mellitus and suffer osteoporotic fractures, the question of a connection between these clinical pictures has now arisen.
Modern magnetic resonance imaging and spectroscopy techniques allow detailed and non-invasive characterization of bone marrow in different body regions.
Read more
Low body weight (BMI<20kg/m²) has been shown to be associated with decreased bone density, while obesity has long been associated with high cortical bone mass - the idea of bone health. It has now been proven that obesity also has a negative effect on bone structure. Here, it is not only BMI that is crucial, but also the localization of fat tissue in the body. Visceral fat has a directly damaging effect on bone microarchitecture through dysregulated production and release of cytokines and adipokines. Thus, it has been shown that both type 1 and type 2 diabetic patients have a decreased rate of bone remodeling and very obese patients with type 2 diabetes have an increased risk of fracture. It must be concluded that body weight, or BMI, cannot be the sole measure for estimating bone health. Thus, type 2 diabetes shows reduced bone remodeling with normal or slightly increased bone density, but inferior stability. This means that type 2 diabetes is associated with an increased risk of osteoporotic fracture, even when bone density measurements are unremarkable. Loss of trabecular bone structure in red (hematopoietic) bone marrow is also characterized by increasing infiltration of the bone marrow space with fat cells (bone marrow adipose tissue). In contrast, the yellow bone marrow, which is mainly present in the diaphysis of tabular bones, has particularly large amounts of fat incorporated into the reticulum cells.
For a long time, only the role of "placeholder" was attributed to these fat cells, but it has been shown that they interact with other cells via the production of autocrine, paracrine and endocrine hormones and cytokines, or adipokines, and are thus related to the metabolic state of the entire body. A basic assumption here is that the amount of unsaturated fatty acids in the adipose bone marrow is an important and functional marker for different types of adipocytes. It has been shown that 3 individuals with poorer insulin sensitivity have more unsaturated fatty acids in yellow bone marrow.
Thus, the concept of different types of adipocytes in the bone marrow, with their inherent different fatty acid composition could serve to reconcile the at first glance counterintuitive physiological regulation of bone marrow fat and its response to metabolic perturbations.
In order to show whether and how the composition of the yellow (unsaturated fatty acids) and red (bone marrow adipose tissue) bone marrow differs in healthy individuals, individuals with impaired insulin sensitivity in different age groups and patients with type 2 diabetes, and whether this can be used to detect early changes in the bone matrix with regard to bone density, the proportion of bone marrow adipose tissue in the red bone marrow at different locations in the skeleton will be quantified by means of chemical-shift-selective MRI sequences as well as the composition of bone marrow fat in the yellow bone marrow with regard to the proportions of monounsaturated and polyunsaturated fatty acids by means of volume-selective MRS.
A total of 96 healthy volunteers (48 each male and female) aged 25 to 75 years and with body mass index between 18.5 and 35 kg/m² will be included. In addition, 24 patients (12female/12male) with type 2 diabetes will be recruited.
After magnetic resonance examination, anthropometric and metabolic characterization (oral glucose tolerance test) will take place.
- Conditions
- Diabetes Mellitus, Type 2, Osteoporosis, Insulin Resistance
- Being tested
- magnetic resonance examination, anthropometric and metabolic characterization
- Medical subject headings
- Diabetes Mellitus, Type 2, Osteoporosis, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
magnetic resonance examination, anthropometric and metabolic characterizationDiagnostic test
Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
| Study group | Role | What they receive |
|---|---|---|
| Magnetic resonance examination and anthropometric, metabolic characterization | Not described Receives: Diagnostic Test: magnetic resonance examination, anthropometric and metabolic characterization |
What is being measured
The primary outcome is the main question the study is designed to answer.
monounsaturated and polyunsaturated fatty acids in the yellow bone marrow
The composition of the lipids in the yellow bone marrow (monounsaturated and polyunsaturated fatty acids) will be determined by volume selective Proton magnetic resonance spectroscopy
Measured: about 10 minutes
Fat content in the red bone marrow of the vertebral bodies and femura
Proton density fat fraction will be determined by multi-echo Dixon-Imaging
Measured: 120 seconds
Fat and water selective tomograms from shoulders to knees
Fat and water selective tomograms from shoulders to knees will be created by chemical-shift-selective recording technique
Measured: 68 seconds
Insulin sensitivity
Insulin sensitivity will be examined by oral glucose tolerance test
Measured: Sample collection will be from 0 to 120 minutes (every 30 minutes)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2021
- Study start7 Jul 2021
- Primary completion25 Apr 2023
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- More trials run by University Hospital TuebingenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 85 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Tuebingen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04950283
- Sponsor's protocol ID
- Knoma
- Status last verified
- May 2024
- First submitted
- 23 Jun 2021
- Last updated
- 14 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MR-basierte Charakterisierung Des Knochenmarks in Seiner Bedeutung für Skeletterkrankungen Von Patienten Mit Diabetes
- ClinicalTrials.gov ID
- NCT04950283
- Acronym / sponsor ID
- Knoma
- Conditions
- Diabetes Mellitus, Type 2, Osteoporosis, Insulin Resistance
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 85 participants (actual)
- Lead sponsor
- University Hospital TuebingenUniversity, hospital or other
- Study start
- 7 Jul 2021 (actual)
- Primary completion
- 25 Apr 2023 (actual)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 6 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
For a long time, no direct connection was seen between the two common diseases diabetes mellitus and osteoporosis. However, as more and more younger people are affected by obesity, develop type 2 diabetes mellitus and suffer osteoporotic fractures, the question of a connection between these clinical pictures has now arisen.
Modern magnetic resonance imaging and spectroscopy techniques allow detailed and non-invasive characterization of bone marrow in different body regions.
Low body weight (BMI<20kg/m²) has been shown to be associated with decreased bone density, while obesity has long been associated with high cortical bone mass - the idea of bone health. It has now been proven that obesity also has a negative effect on bone structure. Here, it is not only BMI that is crucial, but also the localization of fat tissue in the body. Visceral fat has a directly damaging effect on bone microarchitecture through dysregulated production and release of cytokines and adipokines. Thus, it has been shown that both type 1 and type 2 diabetic patients have a decreased rate of bone remodeling and very obese patients with type 2 diabetes have an increased risk of fracture. It must be concluded that body weight, or BMI, cannot be the sole measure for estimating bone health. Thus, type 2 diabetes shows reduced bone remodeling with normal or slightly increased bone density, but inferior stability. This means that type 2 diabetes is associated with an increased risk of osteoporotic fracture, even when bone density measurements are unremarkable. Loss of trabecular bone structure in red (hematopoietic) bone marrow is also characterized by increasing infiltration of the bone marrow space with fat cells (bone marrow adipose tissue). In contrast, the yellow bone marrow, which is mainly present in the diaphysis of tabular bones, has particularly large amounts of fat incorporated into the reticulum cells.
For a long time, only the role of "placeholder" was attributed to these fat cells, but it has been shown that they interact with other cells via the production of autocrine, paracrine and endocrine hormones and cytokines, or adipokines, and are thus related to the metabolic state of the entire body. A basic assumption here is that the amount of unsaturated fatty acids in the adipose bone marrow is an important and functional marker for different types of adipocytes. It has been shown that 3 individuals with poorer insulin sensitivity have more unsaturated fatty acids in yellow bone marrow.
Thus, the concept of different types of adipocytes in the bone marrow, with their inherent different fatty acid composition could serve to reconcile the at first glance counterintuitive physiological regulation of bone marrow fat and its response to metabolic perturbations.
In order to show whether and how the composition of the yellow (unsaturated fatty acids) and red (bone marrow adipose tissue) bone marrow differs in healthy individuals, individuals with impaired insulin sensitivity in different age groups and patients with type 2 diabetes, and whether this can be used to detect early changes in the bone matrix with regard to bone density, the proportion of bone marrow adipose tissue in the red bone marrow at different locations in the skeleton will be quantified by means of chemical-shift-selective MRI sequences as well as the composition of bone marrow fat in the yellow bone marrow with regard to the proportions of monounsaturated and polyunsaturated fatty acids by means of volume-selective MRS.
A total of 96 healthy volunteers (48 each male and female) aged 25 to 75 years and with body mass index between 18.5 and 35 kg/m² will be included. In addition, 24 patients (12female/12male) with type 2 diabetes will be recruited.
After magnetic resonance examination, anthropometric and metabolic characterization (oral glucose tolerance test) will take place.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Magnetic resonance examination and anthropometric, metabolic characterization | – | Diagnostic Test: magnetic resonance examination, anthropometric and metabolic characterization |
Who may qualify
- Ages
- 25 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- community sample
Key inclusion criteria (4 listed)
- Body mass index between 18,5 and 35 kg/m²
- Age between 25 and 75 years
- Ability to understand and follow study-related instructions
- Consent to information in case of unexpected detected pathological findings
Key exclusion criteria (13 listed)
- contraindications for magnetic resonance imaging (metal in or on the body, e.g. pacemaker)
- pregnancy
- people with limited thermal sensors or increased sensitivity to heating
- Persons in whom circulatory disease cannot be excluded after questioning
- Individuals who report a hearing disorder or increased sensitivity to loud sounds
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| magnetic resonance examination, anthropometric and metabolic characterizationParticipants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test. | Diagnostic test | Magnetic resonance examination and anthropometric, metabolic characterization |
Primary outcome
monounsaturated and polyunsaturated fatty acids in the yellow bone marrow
Time frame: about 10 minutes
The composition of the lipids in the yellow bone marrow (monounsaturated and polyunsaturated fatty acids) will be determined by volume selective Proton magnetic resonance spectroscopy
Fat content in the red bone marrow of the vertebral bodies and femura
Time frame: 120 seconds
Proton density fat fraction will be determined by multi-echo Dixon-Imaging
Fat and water selective tomograms from shoulders to knees
Time frame: 68 seconds
Fat and water selective tomograms from shoulders to knees will be created by chemical-shift-selective recording technique
Insulin sensitivity
Time frame: Sample collection will be from 0 to 120 minutes (every 30 minutes)
Insulin sensitivity will be examined by oral glucose tolerance test
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2024.
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Mellitus, Type 2 and Osteoporosis, run by University Hospital Tuebingen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
monounsaturated and polyunsaturated fatty acids in the yellow bone marrow (time frame: about 10 minutes). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2024.